Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.20.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating expenses:        
Research and development $ 2,455,822 $ 391,914 $ 5,166,485 $ 616,325
Acquired in-process research and development 6,826,495 6,826,495
General and administrative 2,484,148 1,012,290 4,753,428 1,212,588
Loss from operations (11,766,465) (1,404,204) (16,746,408) (1,828,913)
Interest income (expense) (3,798) (11,855) 10,344 (162,873)
Foreign exchange loss (8,787) (8,787)
Net loss $ (11,779,050) $ (1,416,059) $ (16,744,851) $ (1,991,786)
Per share information:        
Net loss per share of common stock, basic and diluted $ (1.05) $ (0.26) $ (2.23) $ (0.38)
Weighted average shares outstanding, basic and diluted 11,263,559 5,476,981 7,518,091 5,291,836